Kolexia
Pegourie-Bandelier Brigitte Médecine interne
Pegourie-Bandelier Brigitte
Médecine interne
Hôpital Nord Grenoble
La Tronche, France
127 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Myélome multiple Tumeurs à plasmocytes Récidive tumorale locale Leucémies Maladie résiduelle Leucémie chronique lymphocytaire à cellules B Aberrations des chromosomes Leucémie lymphoïde Macroglobulinémie de Waldenström

Collaborateurs

Voir plus
Moreau Philippe
Moreau Philippe
Hôpital Hôtel-Dieu Nantes, Nantes, France
Facon Thierry
Facon Thierry
Hôpital Huriez, Lille, France
Garderet Laurent
Garderet Laurent
Hôpital Pitie Salpetriere, Paris, France
Hulin Cyrille
Hulin Cyrille
Hôpital Haut-lévêque, Pessac, France

Industries

Voir plus
Celgene
3 collaboration(s)
Dernière en 2018
Takeda Pharmaceutical
2 collaboration(s)
Dernière en 2018
Janssen
1 collaboration(s)
Dernière en 2018
Sebia
1 collaboration(s)
Dernière en 2018

Dernières activités

Voir plus
PCD: A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial
Essai Clinique (Celgene)   03 juillet 2023
Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma: A Phase 1/2 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Multiple Myeloma
Essai Clinique (Abbvie)   16 mars 2023
A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma: A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral Ixazomib (MLN9708) Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Essai Clinique (Takeda Pharmaceutical)   07 février 2023
Phase II Study of the Combination of Pomalidomide with Dexamethasone As Maintenance Therapy after First Relapse Treatment with PCD Followed or Not By Autologous Stem Cell Transplant in Multiple Myeloma Patients
Blood   23 novembre 2021
A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial.
Blood   22 juillet 2021
BVD: A Phase II Study of Bendamustine, Velcade and Dexamethasone (BVD) in the Treatment of Elderly Patients (>= 65 Years) With Multiple Myeloma in 1st Relapse or Refractory to 1st Line Therapy
Essai Clinique (Intergroupe Francophone du Myélome)   03 décembre 2020
Randomized Trial Comparing Double Versus Triple Bortezomib-Based Regimen in Patients With Multiple Myeloma and Acute Kidney Injury Due to Cast Nephropathy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   23 juin 2020
Maintenance of Long-Term Undetectable Minimal Residual Disease after Combination of Ibrutinib with Abbreviated Chemotherapy in the Icll-07 Filo Trial
Blood   13 novembre 2019
Twice Weekly Induction with Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination Followed By Extended IRD Consolidation and Lenalidomide Maintenance in Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du Myelome (IFM 2014-03)
Blood   13 novembre 2019
FIRST: A Phase III, Randomized, Open-label, 3-arm Study to Determine the Efficacy and Safety of Lenalidomide(REVLIMID) Plus Low-dose Dexamethasone When Given Until Progressive Disease or for 18 Four-week Cycles Versus the Combination of Melphalan, Prednisone, and Thalidomide Given for 12 Six-week Cycles in Patients With Previously Untreated Multiple Myeloma Who Are Either 65 Years of Age or Older or Not Candidates for Stem Cell Transplantation.
Essai Clinique (Celgene)   07 novembre 2019